ACADIA Pharmaceuticals Inc logo

ACAD - ACADIA Pharmaceuticals Inc Share Price

$42.68 -0.7  -1.6%

Last Trade - 3:55pm

Sector
Healthcare
Size
Large Cap
Market Cap £5.10bn
Enterprise Value £4.58bn
Revenue £230.2m
Position in Universe 1021st / 6416
Bullish
Bearish
Unlock ACAD Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ACAD Revenue Unlock ACAD Revenue

Net Income

ACAD Net Income Unlock ACAD Revenue

Normalised EPS

ACAD Normalised EPS Unlock ACAD Revenue

PE Ratio Range

ACAD PE Ratio Range Unlock ACAD Revenue

Dividend Yield Range

ACAD Dividend Yield Range Unlock ACAD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ACAD EPS Forecasts Unlock ACAD Revenue
Profile Summary

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors. The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated January 16, 1997
Public Since May 27, 2004
No. of Shareholders: 36,000
No. of Employees: 490
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 153,539,153
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ACAD Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ACAD
Upcoming Events for ACAD
Monday 24th February, 2020 Estimate
Q4 2019 ACADIA Pharmaceuticals Inc Earnings Release
Wednesday 29th April, 2020 Estimate
Q1 2020 ACADIA Pharmaceuticals Inc Earnings Release
Thursday 25th June, 2020 Estimate
ACADIA Pharmaceuticals Inc Annual Shareholders Meeting
Similar to ACAD
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.